• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Females have an increased risk of short ‐term mortality after cardiac surgery compared to males: Insights from a national database
ConclusionFemales in the United Kingdom have an increased risk of short-term mortality after cardiac surgery compared to males. This highlights the need to focus on the understanding of the causes behind these disparities and implementation of strategies to improve outcomes in females.
Source: Journal of Cardiac Surgery - September 18, 2022 Category: Cardiovascular & Thoracic Surgery Authors: Lauren Kari Dixon, Arnaldo Dimagli, Ettorino Di Tommaso, Shubhra Sinha, Daniel P. Fudulu, Manraj Sandhu, Umberto Benedetto, Gianni D. Angelini Tags: ORIGINAL ARTICLE Source Type: research

Re ‐sternotomy for aortic valve replacement in octogenarian patients in age of evolving transcatheter therapies
ConclusionRedoSAVR in octogenarians is associated with significant morbidity and mortality. Shared decision-making should consider emerging transcatheter therapies as a valuable option in selected patients.
Source: Journal of Cardiac Surgery - February 18, 2022 Category: Cardiovascular & Thoracic Surgery Authors: Suvitesh Luthra, Pietro G. Malvindi, Hannah Masraf, Anna Podonyi, Taha Ramadan, Sunil K. Ohri Tags: ORIGINAL ARTICLE Source Type: research

Apical versus subclavian transcatheter aortic valve implantation: An 8 ‐year United Kingdom analysis
ConclusionsAccording to our results, TA provided the best 12-month  survival compared to SC, while the long-term survival up to 2900 days is not significantly different between groups, so SC and TA may both represent a safe non-femoral access if femoral is precluded.
Source: Journal of Cardiac Surgery - February 11, 2022 Category: Cardiovascular & Thoracic Surgery Authors: Francesca D'Auria, Danilo F. Santo, Aung Myat, Roberto Lorusso, Justine M. Ravaux, Uday Trivedi, David Hildick ‐Smith Tags: ORIGINAL ARTICLE Source Type: research

FDA Approves Two New Indications for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, Dec. 20, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved two pediatric indications for XARELTO® (rivaroxaban): the treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients from birth to less than 18 years after at least five days of initial parenteral (injected or intravenous) anticoagulant treatment; and thromboprophylaxis (prevention of blood clots and blood-clot related events) in children aged two years and older with congenital heart disease who have...
Source: Johnson and Johnson - December 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Long-Term Survival and Outcomes According to VARC-2 Criteria for Subclavian, Direct Aortic, Femoral, and Apical Implantation: An 8-Year United Kingdom TAVI Surgical Experience.
CONCLUSIONS: This was a large study that compared outcomes and long-term survival among different TAVI surgical approaches in a national real-world setting. According to our results, SF provided the best survival. While SC provided worse survival than SF, it was still better than TA and DA, and thus may represent the safest non-femoral access if use of the femoral approach is precluded. PMID: 32819023 [PubMed - as supplied by publisher]
Source: Surgical Technology International - August 21, 2020 Category: Surgery Tags: Surg Technol Int Source Type: research

Edwards Lifesciences wins CE Mark for Sapien 3 Ultra TAVR
Edwards Lifesciences (NYSE:EW) said today it won CE Mark approval in the European Union for its Sapien 3 Ultra transcatheter aortic valve replacement system intended for patients with severe, symptomatic aortic stenosis. Despite winning a CE Mark, Edwards said that the new valve will not be launched in Germany due to a preliminary injunction from rival Boston Scientific (NYSE:BSX). The company said that “the German court will hold a full hearing on the merits of the dispute” mid-next year, and that it is hopeful it will prevail. The company said it will introduce the Sapien 3 Ultra in the rest of Europe as pa...
Source: Mass Device - November 16, 2018 Category: Medical Devices Authors: Fink Densford Tags: Cardiac Implants Cardiovascular Featured Regulatory/Compliance Replacement Heart Valves Edwards Lifesciences Source Type: news

Neovasc touts Tiara TMVR success rate in study
A small study of the Neovasc (NSDQ:NVCN) Tiara transcatheter mitral valve replacement (TMVR) in high-risk patients revealed a 100% procedural success rate and immediate elimination of mitral regurgitation. Published in Circulation: Cardiovascular Interventions, the study also showed no death, myocardial infarction, stroke, major bleeding, or access site complications at 30 days. The twelve patients in the study had had a previous aortic valve replacement. Such patients have been excluded from most TMVR trials because of the potential risks of left ventricular outflow tract obstruction or interaction between the TMVR anch...
Source: Mass Device - October 16, 2018 Category: Medical Devices Authors: Nancy Crotti Tags: Blog Cardiac Implants Cardiovascular Featured Replacement Heart Valves Research & Development Mayo Clinic neovasc Neovasc Inc. Source Type: news

Pre-treatment clinical assessment in head and neck cancer: United Kingdom National Multidisciplinary Guidelines.
Authors: Robson A, Sturman J, Williamson P, Conboy P, Penney S, Wood H Abstract This is the official guideline endorsed by the specialty associations involved in the care of head and neck cancer patients in the UK. This paper provides recommendations on the pre-treatment clinical assessment of patients presenting with head and neck cancer. Recommendations • Comorbidity data should be collected as it is important in the analysis of survival, quality of life and functional outcomes after treatment as well as for comparing results of different treatment regimens and different centres. (R) • Patients with hypertens...
Source: Journal of Laryngology and Otology - November 15, 2016 Category: ENT & OMF Tags: J Laryngol Otol Source Type: research